Request Legal Help Now - Free

Advertisement
LAWSUITS NEWS & LEGAL INFORMATION

Fibrinogen Hepatitis

Tokyo, Japan: (Nov-01-07) Five lawsuits were brought against Mitsubishi Tanabe Pharma Corp., a Japanese pharmaceutical company, alleging that customers who used Fibrinogen, which is used to stop bleeding, ended up victims of hepatitis virus-tainted blood products. Mitsubishi Tanabe, a newly merged firm that incorporates the producer of the medical product under state license, said it had agreed to reach a settlement in five lawsuits filed over the disease.

As part of the settlement agreement, the company agreed to pay 2.1 billion yen ($18.17 million) to resolve the case. The government and the company estimate at least 10,000 Japanese people have been infected with potentially fatal hepatitis C after being administered with Fibrinogen. Sources stated that Fibrinogen was widely used at Japanese hospitals until 1988, mostly during surgeries or after women gave birth, even though the US government had warned the public of its danger in 1977. The company is being targeted for its failure to respond to requests by victims for information disclosure and to swiftly notify people who might have contracted the disease. [YAHOO: FIBRINOGEN HEPATITIS]


Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.
Published on Nov-3-07


ADD YOUR COMMENT ON THIS ISSUE

Please read our comment guidelines before posting.


Note: Your name will be published with your comment.


Your email will only be used if a response is needed.

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.

Request Legal Help Now! - Free